99mTc-mercaptoacetyltriglycine (MAG3) is a new renal radiopharmaceutical which has been shown to have biological properties similar to131I-hippurate (OIH) in animals and volunteers.99mTc-MAG3 has now been compared with131I-orthoiodohippurate (OIH) in a group of patients with varying degrees of renal impairment. In all cases, the99mTc-MAG3 images were superior regardless of serum creatinine. Selected examples are illustrated including scans and renogram curves in a normal volunteer, transplant patients with creatinines of 9.8 mg/dl and 2.6 mg/dl respectively, and a furosemide study in a patient with questionable obstruction. Our preliminary results suggest that99mTc-MAG3 performs well in patients with impaired renal function and may well provide an acceptable replacement for OIH. A kit formulation has been developed and will soon be undergoing clinical evaluation. © 1987 Springer-Verlag.
CITATION STYLE
Taylor, A., Eshima, D., & Alazraki, N. (1987). 99mTc-MAG3, a new renal imaging agent: Preliminary results in patients. European Journal of Nuclear Medicine, 12(10), 510–514. https://doi.org/10.1007/BF00620476
Mendeley helps you to discover research relevant for your work.